NANOG and acute myeloid leukemia: To examine the potential impact of these factors on NANOG activation in AML we first determined their expression levels in NOMO-1 in comparison to myeloid control cell lines by RNA-sequencing (S8A Fig), RQ-PCR and western blot (Fig 7A).